These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 15359929)
1. Multifactorial analysis on the short-term side effects occurring within 96 hours after radioiodine-131 therapy for differentiated thyroid carcinoma. Kita T; Yokoyama K; Higuchi T; Kinuya S; Taki J; Nakajima K; Michigishi T; Tonami N Ann Nucl Med; 2004 Jun; 18(4):345-9. PubMed ID: 15359929 [TBL] [Abstract][Full Text] [Related]
2. Effects of Radioiodine Treatment on Salivary Gland Function in Patients with Differentiated Thyroid Carcinoma: A Prospective Study. Klein Hesselink EN; Brouwers AH; de Jong JR; van der Horst-Schrivers AN; Coppes RP; Lefrandt JD; Jager PL; Vissink A; Links TP J Nucl Med; 2016 Nov; 57(11):1685-1691. PubMed ID: 27339871 [TBL] [Abstract][Full Text] [Related]
4. Influence of 131I diagnostic dose on subsequent ablation in patients with differentiated thyroid carcinoma: discrepancy between the presence of visually apparent stunning and the impairment of successful ablation. Hu YH; Wang PW; Wang ST; Lee CH; Chen HY; Chou FF; Huang YE; Huang HH Nucl Med Commun; 2004 Aug; 25(8):793-7. PubMed ID: 15266173 [TBL] [Abstract][Full Text] [Related]
5. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review. Jarzab B; Handkiewicz-Junak D; Wloch J Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322 [TBL] [Abstract][Full Text] [Related]
6. [Salivary gland damage after 131I therapy in patients with differentiated thyroid cancer. Preliminary report]. Macioszek A; Baczyk M; Kopeć T; Sowiński J Endokrynol Pol; 2008; 59(5):403-10. PubMed ID: 18979451 [TBL] [Abstract][Full Text] [Related]
7. Treatment of advanced differentiated thyroid carcinoma with high activity radioiodine therapy. Haq MS; McCready RV; Harmer CL Nucl Med Commun; 2004 Aug; 25(8):799-805. PubMed ID: 15266174 [TBL] [Abstract][Full Text] [Related]
8. Salivary gland toxicity after radioiodine therapy for thyroid cancer. Hyer S; Kong A; Pratt B; Harmer C Clin Oncol (R Coll Radiol); 2007 Feb; 19(1):83-6. PubMed ID: 17305259 [TBL] [Abstract][Full Text] [Related]
9. Relationship between cumulative radiation dose and salivary gland uptake associated with radioiodine therapy of thyroid cancer. Jentzen W; Schneider E; Freudenberg L; Eising EG; Görges R; Müller SP; Brandau W; Bockisch A Nucl Med Commun; 2006 Aug; 27(8):669-76. PubMed ID: 16829767 [TBL] [Abstract][Full Text] [Related]
10. Symptomatic late-onset sialadenitis after radioiodine therapy in thyroid cancer. An YS; Yoon JK; Lee SJ; Song HS; Yoon SH; Jo KS Ann Nucl Med; 2013 May; 27(4):386-91. PubMed ID: 23389626 [TBL] [Abstract][Full Text] [Related]
11. Short-Term Side Effects after Radioiodine Treatment in Patients with Differentiated Thyroid Cancer. Lu L; Shan F; Li W; Lu H Biomed Res Int; 2016; 2016():4376720. PubMed ID: 26989683 [TBL] [Abstract][Full Text] [Related]
12. Iodine kinetics and dosimetry in the salivary glands during repeated courses of radioiodine therapy for thyroid cancer. Liu B; Huang R; Kuang A; Zhao Z; Zeng Y; Wang J; Tian R Med Phys; 2011 Oct; 38(10):5412-9. PubMed ID: 21992360 [TBL] [Abstract][Full Text] [Related]
14. Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma. Alexander C; Bader JB; Schaefer A; Finke C; Kirsch CM J Nucl Med; 1998 Sep; 39(9):1551-4. PubMed ID: 9744341 [TBL] [Abstract][Full Text] [Related]
15. Radioiodine treatment complications to the mother and child in patients with differentiated thyroid carcinoma. Fard-Esfahani A; Hadifar M; Fallahi B; Beiki D; Eftekhari M; Saghari M; Takavar A Hell J Nucl Med; 2009; 12(1):37-40. PubMed ID: 19330181 [TBL] [Abstract][Full Text] [Related]
16. Radioprotection of salivary glands by amifostine in high-dose radioiodine treatment. Results of a double-blinded, placebo-controlled study in patients with differentiated thyroid cancer. Bohuslavizki KH; Klutmann S; Brenner W; Kröger S; Buchert R; Bleckmann C; Mester J; Henze E; Clausen M Strahlenther Onkol; 1999 Nov; 175 Suppl 4():6-12. PubMed ID: 10584133 [TBL] [Abstract][Full Text] [Related]
17. Is empiric 131I therapy justified for patients with positive thyroglobulin and negative 131I whole-body scanning results? Ma C; Xie J; Kuang A J Nucl Med; 2005 Jul; 46(7):1164-70. PubMed ID: 16000286 [TBL] [Abstract][Full Text] [Related]
18. Quantitative evaluation of salivary gland dysfunction after radioiodine therapy using salivary gland scintigraphy. Raza H; Khan AU; Hameed A; Khan A Nucl Med Commun; 2006 Jun; 27(6):495-9. PubMed ID: 16710103 [TBL] [Abstract][Full Text] [Related]
19. Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy. Bohuslavizki KH; Brenner W; Klutmann S; Hübner RH; Lassmann S; Feyerabend B; Lüttges J; Tinnemeyer S; Clausen M; Henze E J Nucl Med; 1998 Jul; 39(7):1237-42. PubMed ID: 9669401 [TBL] [Abstract][Full Text] [Related]
20. The dental safety profile of high-dose radioiodine therapy for thyroid cancer: long-term results of a longitudinal cohort study. Walter MA; Turtschi CP; Schindler C; Minnig P; Müller-Brand J; Müller B J Nucl Med; 2007 Oct; 48(10):1620-5. PubMed ID: 17873131 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]